Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim - LARVOL DELTA

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=252 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US. (PubMed, JAMA Dermatol) - "In 2021, costs ranged from $12 413 (infliximab) to $70 043 (risankizumab). This cross-sectional study found that from 2007 to 2021, treatment costs increased for biologic medications used to treat plaque psoriasis. Substantial savings are available if more patients and physicians use the lowest-cost options and/or if drug prices were better aligned with the comparative effectiveness and safety of each medication."

Journal • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Rheumatology • IL12A • IL17A • IL23A

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Severe Epistaxis Due to Risankizumab: A Case Report. (PubMed, Cureus) - "The most common of these reported adverse effects, affecting more than 20% of users, is nasopharyngitis. This case report discusses a 76-year-old female patient who presented to the emergency department for severe epistaxis while receiving risankizumab as treatment for plaque psoriasis."

Journal • Dermatology • Immunology • Infectious Disease • Psoriasis

Risankizumab-Rzaa in the Management of Birdshot Chorioretinopathy: A Case Report. (PubMed, Ocul Immunol Inflamm) - "Risankizumab-rzaa may be an effective treatment for BSCR. Further studies are needed to establish long-term efficacy for this medication in treating such forms of uveitis."

Journal • Achromatopsia • Crohn's disease • Dermatology • Gastroenterology • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Macular Edema • Ocular Inflammation • Ophthalmology • Psoriasis • Psoriatic Arthritis • Retinal Disorders • Rheumatology • Seronegative Spondyloarthropathies • Uveitis

APPRISE: An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) (clinicaltrials.gov) - P=N/A | N=1000 | Recruiting | Sponsor: AbbVie | Trial completion date: Jan 2028 ➔ Jul 2028 | Trial primary completion date: Jan 2028 ➔ Jul 2028

Adverse events • Real-world evidence • Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease. (PubMed, Gastro Hep Adv) - "In the integrated analysis, a lower incidence rate per 100 PYs of CD-related hospitalizations was observed in the risankizumab-treated groups (600 mg IV/360 mg SC: 9.6; 600 mg IV/180 mg SC: 7.9) vs placebo (40.0, P < .001). Risankizumab treatment resulted in reduced rates of CD-related hospitalization with treatment effect observed within 12 weeks of randomization."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (ISPOR 2025) - "Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private"

Dermatology • Immunology • Inflammation • Psoriasis

IL23p19 therapies for moderately-to-severely active ulcerative colitis. (PubMed, Expert Opin Biol Ther) - "In this review, we summarize and discuss phase 2 and pivotal phase 3 clinical trials informing the efficacy and safety of mirikizumab (AMAC, LUCENT, SHINE), risankizumab (INSPIRE, COMMAND), and guselkumab (QUASAR, VEGA)...These well-tolerated agents are effective in both advanced treatment-naïve and experienced patients. Accordingly, IL23p19 antagonists have potential to be used in a diverse population of patients with UC, and as potential platform therapies for future combinations with other targeted immunomodulatory agents."

Journal • Review • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL23A

Real-World Treatment Patterns Among Patients With Scalp Psoriasis in Canada (ISPOR 2025) - "More than half of the patients with scalp psoriasis were treated with an advanced systemic therapy; the three most common were risankizumab (26%), guselkumab (18%), and apremilast (10%). Scalp psoriasis was present in a substantial proportion of patients with plaque psoriasis in Canada, identified in more than one-third of patients in the DERMAID database. Patients with scalp psoriasis are likely to receive advanced systemic therapy, with more than half of the patients having received this treatment. Even when BSA <10% is present, indicative of mild-to-moderate psoriasis that can be managed topically, a sizable proportion of patients (20%) received advanced therapy."

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics (clinicaltrials.gov) - P4 | N=56 | Recruiting | Sponsor: University Hospitals Cleveland Medical Center | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis • IL12A

Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. (PubMed, Front Immunol) - "However, in a co-culture of IL-23-producing CD64+ THP-1 cells with an IL-23-responsive reporter cell line, guselkumab demonstrated Fc-dependent enhanced potency compared to risankizumab for inhibiting IL-23 signaling. These in vitro data highlight the potential for guselkumab binding to CD64 in inflamed tissue to contribute to the potent neutralization of IL-23 at its cellular source."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL23A

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers. (PubMed, Australas J Dermatol) - "A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis."

Journal • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis • IL23A

Corticosteroid-Sparing Effects of Risankizumab Efficacy and Safety in Patients With Moderately to Severely Active Ulcerative Colitis. (PubMed, J Crohns Colitis) - "Efficacy of RZB induction therapy was independent of corticosteroid use, with high rates of corticosteroid-free outcomes observed in the overall population and among patients with baseline corticosteroid use, reaffirming the potential of RZB to serve as a corticosteroid-sparing therapy for patients with ulcerative colitis."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Prometheus Laboratories Launches New Anser(R) Test for Risankizumab (ACCESSWIRE) - "Prometheus Laboratories Inc...announces a new Anser therapeutic drug monitoring (TDM) test for risankizumab (RZB). Anser RZB is a clinically validated TDM testing solution that enables prescribers treating Crohn's disease, ulcerative colitis, plaque psoriasis or psoriatic arthritis patients to quantitatively measure drug and anti-drug antibody levels to guide their clinical decisions."

Clinical • Crohn's disease • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

Cost-per-Event Analysis of Risankizumab in Comparison to Ustekinumab for the Treatment of Patients With Moderate-to-Severe Crohn's Disease in Brazil (ISPOR 2025) - "In the Brazilian healthcare system, RZB was associated with lower cost-per-event compared to UST for patients with moderate-to-severe CD who have failed iTNF therapy. These findings indicate that resource allocation strategies could increase the number of patients receiving effective therapy for CD with RZB compared to UST."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • Oncology

Real-World Effectiveness and Satisfaction With Risankizumab for the Treatment of Early Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe (EULAR 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients With Active Psoriatic Arthritis Treated With Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials (EULAR 2025) - No abstract available

Clinical • P3 data • Patient reported outcomes • Retrospective data • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Correction to: P0722 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension. (PubMed, J Crohns Colitis) - No abstract available

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Clinical Experience of Risankizumab in Patients With a History of Erythrodermic Psoriasis. (PubMed, Exp Dermatol) - "Among patients with a history of EP, those with prior exposure to guselkumab and those treated with more than five biologics demonstrated a decreased response to risankizumab. However, prior exposure to multiple biologics, particularly those with a similar mode of action targeting IL-23, may reduce its effectiveness. The potential association between HLA-Cw1 genotype and treatment response warrants further investigation."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL23A

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy. (PubMed, Dermatol Pract Concept) - "Risankizumab showed superior efficacy than secukinumab and a lower cost per responder."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: AbbVie | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: Jan 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Acyclovir-induced sinus bradycardia: a case report and literature review. (PubMed, Encephalitis) - "Her relevant medical history included rheumatoid arthritis which was treated with risankizumab. This is the third reported case of sinus bradycardia potentially linked to acyclovir administration. Thus, clinicians should consider intravenous acyclovir as a possible cause of de novo sinus bradycardia."

Journal • Cardiovascular • Epstein-Barr Virus Infections • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology • Varicella Zoster

REVAMP: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (clinicaltrials.gov) - P3 | N=530 | Not yet recruiting | Sponsor: AbbVie

New P3 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Persistence and Efficacy of Ustekinumab in Crohn's Disease After Anti-TNF Failure: An Observational Study. (PubMed, Dig Dis Sci) - "Ustekinumab may have better persistence as a second-line treatment compared to anti-TNF and may be effective in perianal disease."

Journal • Observational data • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease